(Q46155885)

20 December 2017

title

A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy (English)

1 reference

20 December 2017

1 reference

1 reference

placebo-controlled trial

1 reference

1 reference

1 reference

Rajesh V Lalla

1

1 reference

20 December 2017

Gary B Gordon

2

1 reference

20 December 2017

Mark Schubert

3

1 reference

20 December 2017

Sol Silverman

4

1 reference

20 December 2017

Mark Hutten

5

1 reference

20 December 2017

Stephen T Sonis

6

1 reference

20 December 2017

Francis LeVeque

7

1 reference

20 December 2017

Douglas E Peterson

8

1 reference

20 December 2017

publication date

1 October 2011

1 reference

20 December 2017

Supportive Care in Cancer

published in

1 reference

20 December 2017

volume

20

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

page(s)

1797-1804

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1007/s00520-011-1277-7

exact match

0 references

cites work

Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Mucositis in the cancer patient and immunosuppressed host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Treatment of mucositis, including new medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Anti-inflammatory agents in the management of alimentary mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Management of oral mucositis in patients who have cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Oral complications and management considerations in patients treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-011-1277-7

Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.

21 January 2018

1 reference

12 December 2020

Patient reports of complications of bone marrow transplantation

1 reference

12 December 2020

Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants

1 reference

12 December 2020

Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT--results of a multicentre study

1 reference

12 December 2020

Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin

1 reference

12 December 2020

Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: a placebo controlled double blind clinical trial

1 reference

12 December 2020

Misoprostol prevents damage to the gastric mucosa by stabilizing the mast cells

1 reference

12 December 2020

Protection from Radiation-Induced Oral Mucositis by Misoprostol, a Prostaglandin E(1) Analog: A Placebo-Controlled, Double-Blind Clinical Trial

1 reference

12 December 2020

Misoprostol: a prostaglandin E1 analogue.

1 reference

12 December 2020

Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report

1 reference

12 December 2020

An investigation of misoprostol in the promotion of wound healing.

1 reference

12 December 2020

Effect of Misoprostol on Acute and Chronic Inflammation

1 reference

12 December 2020

The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies.

1 reference

12 December 2020

The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3

1 reference

12 December 2020

10.1007/S00520-011-1277-7

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017